As GLP-1 competition shifts from molecules to prescriptions, manufacturers, pharmacies, providers, and payers are racing to own the patient journey.

Pharma brands with all the right information are still invisible to AI — and why silence is the bigger risk than inaccuracy.

Bristol Myers Squibb’s Wendy Short Bartie on recasting corporate affairs as an enterprise value engine that connects trust, access and the patient voice.

Inizio's Elaine Ferguson on why enabling purpose-driven employees to make a meaningful difference is as important as any formal talent strategy.

Life sciences liability risks change character — not just size — as companies move from R&D to commercialization.

Inizio's Elaine Ferguson on how cross-functional leadership pods tackling real business challenges are turning talent development into operational innovation.

How the shifting tides in information consumption are resetting expectations for pharma in providing and delivering health education.

CGT commercial trajectories are set years before approval — and every development decision is an access decision.